The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected Patients
Completed
Glaxo Wellcome
Phase 1
1969-12-31
To evaluate the safety and tolerability of multiple escalating doses of 1263W94 administered
orally for 28 days in HIV infected patients with asymptomatic CMV shedding. To obtain
preliminary evidence of the in vivo anti CMV activity of different doses of 1263W94 in humans
based on quantitative reduction of CMV load in semen and if possible in other biological
fluids and to explore the dose response relationship in the anti-CMV activity of 1263W94.
Maribavir for Prevention of CMV After Stem Cell Transplants
Completed
Shire
Phase 2
2004-10-28
Cytomegalovirus (CMV) infections remain a significant problem following various types of
transplants that are associated with strong immunosuppressive therapy. Maribavir is a new
oral anti-CMV drug with a novel mechanism of action compared to currently available anti-CMV
drugs. This study will test the safety and anti-CMV activity of different doses of maribavir
when given as CMV prophylaxis following stem cell transplants.
Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients
Completed
Shire
Phase 3
2006-12-13
The purpose of this research study is to investigate whether or not maribavir is safe and
effective for preventing CMV disease when taken by mouth for up to 12 weeks in patients who
have had a stem cell transplant.
Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients
Completed
Shire
Phase 3
2007-07-23
The purpose of this research study is to investigate whether or not oral maribavir is safe
and effective compared to oral ganciclovir for preventing CMV disease when administered for
up to 14 weeks in patients who have had a liver transplant.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
